241 related articles for article (PubMed ID: 26384811)
1. The use of (18)F-FDG PET to differentiate progressive disease from treatment induced necrosis in high grade glioma.
Dankbaar JW; Snijders TJ; Robe PA; Seute T; Eppinga W; Hendrikse J; De Keizer B
J Neurooncol; 2015 Oct; 125(1):167-75. PubMed ID: 26384811
[TBL] [Abstract][Full Text] [Related]
2. Differentiating radiation necrosis from tumor recurrence in high-grade gliomas: assessing the efficacy of 18F-FDG PET, 11C-methionine PET and perfusion MRI.
Kim YH; Oh SW; Lim YJ; Park CK; Lee SH; Kang KW; Jung HW; Chang KH
Clin Neurol Neurosurg; 2010 Nov; 112(9):758-65. PubMed ID: 20619531
[TBL] [Abstract][Full Text] [Related]
3. Optimization of semi-quantification in metabolic PET studies with 18F-fluorodeoxyglucose and 11C-methionine in the determination of malignancy of gliomas.
Borbély K; Nyáry I; Tóth M; Ericson K; Gulyás B
J Neurol Sci; 2006 Jul; 246(1-2):85-94. PubMed ID: 16603193
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic accuracy of
He Q; Zhang L; Zhang B; Shi X; Yi C; Zhang X
BMC Cancer; 2019 Apr; 19(1):332. PubMed ID: 30961564
[TBL] [Abstract][Full Text] [Related]
5. Comparison of (11)C-methionine, (11)C-choline, and (18)F-fluorodeoxyglucose-PET for distinguishing glioma recurrence from radiation necrosis.
Takenaka S; Asano Y; Shinoda J; Nomura Y; Yonezawa S; Miwa K; Yano H; Iwama T
Neurol Med Chir (Tokyo); 2014; 54(4):280-9. PubMed ID: 24305028
[TBL] [Abstract][Full Text] [Related]
6. Comparison of effects of 18F-FDG PET-CT and MRI in identifying and grading gliomas.
Song PJ; Lu QY; Li MY; Li X; Shen F
J Biol Regul Homeost Agents; 2016; 30(3):833-838. PubMed ID: 27655507
[TBL] [Abstract][Full Text] [Related]
7. Integrated PET-MRI for Glioma Surveillance: Perfusion-Metabolism Discordance Rate and Association With Molecular Profiling.
Seligman L; Kovanlikaya I; Pisapia DJ; Naeger DM; Magge R; Fine HA; Chiang GC
AJR Am J Roentgenol; 2019 Apr; 212(4):883-891. PubMed ID: 30779663
[TBL] [Abstract][Full Text] [Related]
8. A surgical strategy using a fusion image constructed from 11C-methionine PET, 18F-FDG-PET and MRI for glioma with no or minimum contrast enhancement.
Ideguchi M; Nishizaki T; Ikeda N; Okamura T; Tanaka Y; Fujii N; Ohno M; Shimabukuro T; Kimura T; Ikeda E; Suga K
J Neurooncol; 2018 Jul; 138(3):537-548. PubMed ID: 29516344
[TBL] [Abstract][Full Text] [Related]
9. Longitudinal DSC-MRI for Distinguishing Tumor Recurrence From Pseudoprogression in Patients With a High-grade Glioma.
Boxerman JL; Ellingson BM; Jeyapalan S; Elinzano H; Harris RJ; Rogg JM; Pope WB; Safran H
Am J Clin Oncol; 2017 Jun; 40(3):228-234. PubMed ID: 25436828
[TBL] [Abstract][Full Text] [Related]
10. Relative value of magnetic resonance spectroscopy, magnetic resonance perfusion, and 2-(18F) fluoro-2-deoxy-D-glucose positron emission tomography for detection of recurrence or grade increase in gliomas.
Prat R; Galeano I; Lucas A; Martínez JC; Martín M; Amador R; Reynés G
J Clin Neurosci; 2010 Jan; 17(1):50-3. PubMed ID: 19959364
[TBL] [Abstract][Full Text] [Related]
11. ¹¹C-methionine and ¹⁸F-fluorodeoxyglucose positron emission tomography/CT in the evaluation of patients with suspected primary and residual/recurrent gliomas.
Li DL; Xu YK; Wang QS; Wu HB; Li HS
Chin Med J (Engl); 2012 Jan; 125(1):91-6. PubMed ID: 22340472
[TBL] [Abstract][Full Text] [Related]
12. [Value of 18F-FDG PET imaging in diagnosing tumor residue of intracranial glioma after surgery and radiotherapy].
Chen YR; Li WX; Lin YR; Chen LH
Ai Zheng; 2004 Oct; 23(10):1210-2. PubMed ID: 15473938
[TBL] [Abstract][Full Text] [Related]
13. 18F-FET PET differentiation of ring-enhancing brain lesions.
Floeth FW; Pauleit D; Sabel M; Reifenberger G; Stoffels G; Stummer W; Rommel F; Hamacher K; Langen KJ
J Nucl Med; 2006 May; 47(5):776-82. PubMed ID: 16644747
[TBL] [Abstract][Full Text] [Related]
14. Glioma recurrence versus radiation necrosis? A pilot comparison of arterial spin-labeled, dynamic susceptibility contrast enhanced MRI, and FDG-PET imaging.
Ozsunar Y; Mullins ME; Kwong K; Hochberg FH; Ament C; Schaefer PW; Gonzalez RG; Lev MH
Acad Radiol; 2010 Mar; 17(3):282-90. PubMed ID: 20060750
[TBL] [Abstract][Full Text] [Related]
15. Multiparametric Evaluation in Differentiating Glioma Recurrence from Treatment-Induced Necrosis Using Simultaneous
Jena A; Taneja S; Jha A; Damesha NK; Negi P; Jadhav GK; Verma SM; Sogani SK
AJNR Am J Neuroradiol; 2017 May; 38(5):899-907. PubMed ID: 28341716
[TBL] [Abstract][Full Text] [Related]
16. Imaging proliferation in brain tumors with 18F-FLT PET: comparison with 18F-FDG.
Chen W; Cloughesy T; Kamdar N; Satyamurthy N; Bergsneider M; Liau L; Mischel P; Czernin J; Phelps ME; Silverman DH
J Nucl Med; 2005 Jun; 46(6):945-52. PubMed ID: 15937304
[TBL] [Abstract][Full Text] [Related]
17. 18-Fluorodeoxyglucose uptake and survival of patients with suspected recurrent malignant glioma.
Barker FG; Chang SM; Valk PE; Pounds TR; Prados MD
Cancer; 1997 Jan; 79(1):115-26. PubMed ID: 8988735
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic accuracy of 11C-methionine PET for differentiation of recurrent brain tumors from radiation necrosis after radiotherapy.
Terakawa Y; Tsuyuguchi N; Iwai Y; Yamanaka K; Higashiyama S; Takami T; Ohata K
J Nucl Med; 2008 May; 49(5):694-9. PubMed ID: 18413375
[TBL] [Abstract][Full Text] [Related]
19. [Combined use of positron emission tomography with (18)F-fluorodeoxyglucose and (11)C-methionine for preoperative evaluation of gliomas].
Yamaguchi S; Terasaka S; Kobayashi H; Narita T; Hirata K; Shiga S; Usui R; Tanaka S; Kubota K; Murata J; Asaoka K
No Shinkei Geka; 2010 Jul; 38(7):621-8. PubMed ID: 20628188
[TBL] [Abstract][Full Text] [Related]
20. 18F-FDG PET of common enhancing malignant brain tumors.
Kosaka N; Tsuchida T; Uematsu H; Kimura H; Okazawa H; Itoh H
AJR Am J Roentgenol; 2008 Jun; 190(6):W365-9. PubMed ID: 18492879
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
